Interstitial cystitis is a prolonged condition that causes bladder pressure, pain, and, in some cases, pelvic pain. The pain ranges from mild discomfort to excruciating pain. It is also known as painful bladder syndrome. It is difficult to diagnose, therefore, while treatments can improve one's quality of life, there is no optimal cure.
The symptoms of interstitial cystitis may cause an impact on one’s social life, physical activity, sleep, and even on the ability to work. The disease tends to effect women more than the men. Common symptoms include bladder pain and pressure, frequent urination, pain in vagina or vulva in case of women and pain in scrotum or testicles in case of men.
Global Interstitial Cystitis Drugs Market – Dynamics
Rising mergers, agreements, and acquisitions by market players are expected to propel the global interstitial cystitis drugs market over the forecast period. For instance, on January 28, 2019, Purdue Pharma L.P. and Alivio Therapeutics (companies based in U.S. involved in the production for prescription medicines) recently confirmed a collaboration to advance one of Alivio's product candidates through clinical development, with Purdue having the option to collaborate on a limited number of additional compounds utilizing Alivio's inflammation-targeting technology known as ALV-107, which is a non-opioid and anti-inflammatory medication for interstitial cystitis/bladder pain syndrome (IC/BPS).These factors are expected to support global interstitial cystitis drugs market growth over the forecast period.
Global Interstitial Cystitis Drugs Market – Regional Insights
North America is expected to witness significant growth in global interstitial cystitis drugs market in the forecast period. As, there is no definite cure for interstitial cystitis currently. This leaves a scope for new drug launches in future. For instance, in December 2019, the U.S. Food and Drugs Administration (FDA) issued a draft guidance, outlining suggestions for the clinical development of new drugs to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS).This ultimately encourages sponsors of biopharmaceutical companies to manufacture and market more drugs related to interstitial cystitis or bladder pain syndrome.
Moreover, due to some recent drug approvals, Europe may witness a lucrative growth in global interstitial cystitis drugs market in the forecast period. For instance, on April 3, 2017, the European Commission announced that Elmiron received European Union (EU) approval for the treatment of bladder pain syndrome/interstitial cystitis in adults with moderate to severe bladder pain and frequent micturition. With Elmiron’s marketing authorization, Bene-Arzneimittel, a pharmaceutical company based in Germany, has the Europe’s first approved drug therapy against interstitial cystitis. These factors are expected to support global interstitial cystitis drugs market growth over the forecast period.
Global Interstitial Cystitis Drugs Market – Taxonomy
By Drug Class:
By Route of Administration:
By Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Global Interstitial Cystitis Drugs Market – Competitive landscape
Key players involved in the global interstitial cystitis drugs market include Purdue Pharma L.P., Alivio Therapeutics, Bayer AG, Janssen Pharmaceuticals Inc., Sandoz (a Novartis division), Bene-Arzneimittel GmbH, and Pfizer Inc.